AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33647246 — intervention group
Group type: COMPARATOR
Intervention: Standard systolic blood pressure target (130-185 mm Hg)
Number of subjects: 324
Study 36165224 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi programme (12 weeks, 45 min per session, twice a week)
Number of subjects: 40
Study 36165224 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 40
Study 34582490 — intervention group
Group type: EXPERIMENTAL
Intervention: Timely first antenatal care visit
Number of subjects: 3293
Study 34582490 — intervention group
Group type: EXPERIMENTAL
Intervention: Four timely antenatal care visits
Number of subjects: 3293
Study 34582490 — intervention group
Group type: EXPERIMENTAL
Intervention: Facility delivery
Number of subjects: 3293
Study 34582490 — intervention group
Group type: EXPERIMENTAL
Intervention: Timely first antenatal care visit associated with age >30 years
Number of subjects: 3293
Study 34582490 — intervention group
Group type: EXPERIMENTAL
Intervention: Timely first antenatal care visit associated with nulliparity
Number of subjects: 3293
Study 34582490 — intervention group
Group type: EXPERIMENTAL
Intervention: Timely first antenatal care visit associated with husband's education >10 years
Number of subjects: 3293
Study 34582490 — intervention group
Group type: EXPERIMENTAL
Intervention: Timely first antenatal care visit associated with highest wealth quintile
Number of subjects: 3293
Study 34582490 — intervention group
Group type: EXPERIMENTAL
Intervention: Facility deliveries associated with woman's age, parity, education, husband's education, and wealth index
Number of subjects: 3293
Study 32722707 — intervention group
Group type: COMPARATOR
Intervention: Garo community
Number of subjects: 1929
Study 32722707 — intervention group
Group type: COMPARATOR
Intervention: Santal community
Number of subjects: 1929
Study 32722707 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall sample
Number of subjects: 1929
Study 36000981 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-1014-6470 30 mg
Number of subjects: 30
Study 36000981 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-1014-6470 60 mg
Number of subjects: 30
Study 36000981 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-1014-6470 120 mg
Number of subjects: 30
Study 36000981 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 34418400 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolebrutinib 5 mg
Number of subjects: 130
Study 34418400 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolebrutinib 15 mg
Number of subjects: 130
Study 34418400 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolebrutinib 30 mg
Number of subjects: 130
Study 34418400 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolebrutinib 60 mg
Number of subjects: 130
Study 34418400 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 36113016 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 L-PEG/Asc
Number of subjects: 240
Study 36113016 — intervention group
Group type: COMPARATOR
Intervention: 2 L-PEG/Asc
Number of subjects: 240
Study 34350598 — intervention group
Group type: EXPERIMENTAL
Intervention: High-status individuals
Number of subjects: 0
Study 34350598 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium impact condition
Number of subjects: 0
Study 34350598 — intervention group
Group type: EXPERIMENTAL
Intervention: High capital third parties
Number of subjects: 0
Study 34350598 — intervention group
Group type: EXPERIMENTAL
Intervention: Resource abundance
Number of subjects: 0
Study 32208229 — intervention group
Group type: EXPERIMENTAL
Intervention: Early discharge (before 28 hours)
Number of subjects: 12
Study 32208229 — intervention group
Group type: COMPARATOR
Intervention: Late discharge (after 48 hours)
Number of subjects: 12
Study 32208229 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation and planning for discharge
Number of subjects: 12
Study 32208229 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional support after discharge
Number of subjects: 12
Study 35459713 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial injection of 20 mg lidocaine
Number of subjects: 136
Study 35459713 — intervention group
Group type: COMPARATOR
Intervention: Intra-arterial saline injection (control)
Number of subjects: 136
Study 32989636 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy-based short-term abstinence intervention (8 sessions of 2.5 hours over 2 weeks)
Number of subjects: 65
Study 32989636 — intervention group
Group type: COMPARATOR
Intervention: Control group (used social media as usual)
Number of subjects: 65
Study 32276664 — intervention group
Group type: EXPERIMENTAL
Intervention: HMD‐VR
Number of subjects: 70
Study 32276664 — intervention group
Group type: COMPARATOR
Intervention: Conventional screen environment
Number of subjects: 70
Study 35590318 — intervention group
Group type: EXPERIMENTAL
Intervention: Transactional analysis training (TEITA)
Number of subjects: 34
Study 35590318 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 34
Study 33635955 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D printed rib model
Number of subjects: 237
Study 33635955 — intervention group
Group type: COMPARATOR
Intervention: Traditional static rib model
Number of subjects: 237
Study 34370025 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% hydrogen peroxide applied once daily for 15 minutes (HP 15)
Number of subjects: 72
Study 34370025 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% hydrogen peroxide applied once daily for 30 minutes (HP 30)
Number of subjects: 72
Study 34370025 — intervention group
Group type: COMPARATOR
Intervention: Both HP 15 and HP 30
Number of subjects: 72
Study 35118998 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Dye (ND) group (no contrast injection)
Number of subjects: 165
Study 35118998 — intervention group
Group type: COMPARATOR
Intervention: Dye (D) group (with contrast injection)
Number of subjects: 165
Study 35118998 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Dye (ND) group
Number of subjects: 165
Study 35118998 — intervention group
Group type: COMPARATOR
Intervention: Dye (D) group
Number of subjects: 165
Study 35118998 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 165
Study 32229033 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-of-bed elevation of 20cm for 6 weeks
Number of subjects: 39
Study 32229033 — intervention group
Group type: COMPARATOR
Intervention: Control group (no head-of-bed elevation)
Number of subjects: 39
Study 32229033 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-of-bed elevation
Number of subjects: 39
Study 36223555 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical mitomycin (MMC) 40 mg/40 mL three times a week for 2 weeks
Number of subjects: 120
Study 36223555 — intervention group
Group type: COMPARATOR
Intervention: TURBT or office biopsy and 6 weekly adjuvant instillations
Number of subjects: 120
Study 34146846 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based education program (five-week duration)
Number of subjects: 118
Study 34146846 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 118
Study 32087502 — intervention group
Group type: COMPARATOR
Intervention: online-sham tDCS
Number of subjects: 23
Study 32087502 — intervention group
Group type: EXPERIMENTAL
Intervention: online-active tDCS
Number of subjects: 23
Study 32087502 — intervention group
Group type: COMPARATOR
Intervention: offline-tDCS
Number of subjects: 23
Study 35276223 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab with Methotrexate (ADL-MTX group)
Number of subjects: 61
Study 35276223 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab Monotherapy (ADL group)
Number of subjects: 61
Study 32018040 — intervention group
Group type: EXPERIMENTAL
Intervention: Myo-inositol (4 g) and folic acid (400 μg) daily
Number of subjects: 112
Study 32018040 — intervention group
Group type: COMPARATOR
Intervention: Folic acid (400 μg) daily
Number of subjects: 112
Study 36424580 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide 20 μg subcutaneously daily for a mean of 18 months (range 14-24 months)
Number of subjects: 40
Study 36424580 — intervention group
Group type: COMPARATOR
Intervention: Population sample (n=233, similar age)
Number of subjects: 40
Study 34870163 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of intra-articular PRP
Number of subjects: 90
Study 34870163 — intervention group
Group type: EXPERIMENTAL
Intervention: Double dose of intra-articular PRP
Number of subjects: 90
Study 34870163 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple dose of intra-articular PRP
Number of subjects: 90
Study 36116392 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 80 mg
Number of subjects: 11
Study 36116392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 33546944 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium intake in 2008–2012: 3147 mg (95% CI 3086–3208) in men; 2784 mg (95% CI 2727–2841) in women.
Number of subjects: 3844
Study 33546944 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate potassium intake (≥ 3510 mg/day) prevalence in 2008–2012: 31% (95% CI 28–34%) for men; 18% (95% CI 16–21%) for women.
Number of subjects: 3844
Study 33546944 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium/potassium ratio.
Number of subjects: 3844
Study 32446706 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (1.5 mA for 20 minutes)
Number of subjects: 33
Study 32446706 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 33
Study 35815086 — intervention group
Group type: EXPERIMENTAL
Intervention: AsmaDroid® app educational content
Number of subjects: 140
Study 35815086 — intervention group
Group type: COMPARATOR
Intervention: Control group (no app)
Number of subjects: 140
Study 35815086 — intervention group
Group type: COMPARATOR
Intervention: Comparison between control and treatment groups
Number of subjects: 140
Study 33862624 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) 'on'
Number of subjects: 6
Study 33862624 — intervention group
Group type: COMPARATOR
Intervention: Deep brain stimulation (DBS) 'off'
Number of subjects: 6
Study 33862624 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-DBS 'on' after crossover
Number of subjects: 6
Study 35195530 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-assessment smartphone app
Number of subjects: 5671
Study 32236999 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram associated with Bacopa monnieri (300 mg bid) for 4 weeks
Number of subjects: 42
Study 32236999 — intervention group
Group type: COMPARATOR
Intervention: Citalopram alone
Number of subjects: 42
Study 32236999 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacopa monnieri extract (50-200 mg kg-1, p.o.) for 1 week in mouse model
Number of subjects: 42
Study 32236999 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacopa monnieri extract
Number of subjects: 42
Study 35084738 — intervention group
Group type: EXPERIMENTAL
Intervention: Delgocitinib cream 1 mg g‐1
Number of subjects: 258
Study 35084738 — intervention group
Group type: EXPERIMENTAL
Intervention: Delgocitinib cream 3 mg g‐1
Number of subjects: 258
Study 35084738 — intervention group
Group type: EXPERIMENTAL
Intervention: Delgocitinib cream 8 mg g‐1
Number of subjects: 258
Study 35084738 — intervention group
Group type: EXPERIMENTAL
Intervention: Delgocitinib cream 20 mg g‐1
Number of subjects: 258
Study 35084738 — intervention group
Group type: COMPARATOR
Intervention: Vehicle treatment
Number of subjects: 258
Study 35084738 — intervention group
Group type: EXPERIMENTAL
Intervention: Delgocitinib cream (8 and 20 mg g‐1)
Number of subjects: 258
Study 35084738 — intervention group
Group type: EXPERIMENTAL
Intervention: Delgocitinib cream
Number of subjects: 258
Study 34789441 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 433
Study 33278671 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1000 mg twice daily) plus chemotherapy (gemcitabine and carboplatin)
Number of subjects: 164
Study 33278671 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1000 mg twice daily) plus chemotherapy in SqCC with high FDG uptake
Number of subjects: 164
Study 33278671 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin group
Number of subjects: 164
Study 33278671 — intervention group
Group type: COMPARATOR
Intervention: Control group (chemotherapy alone)
Number of subjects: 164
Study 33247731 — intervention group
Group type: EXPERIMENTAL
Intervention: Dried Yeast (DY)
Number of subjects: 51
Study 33247731 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean Meal (SBM)
Number of subjects: 51
Study 33247731 — intervention group
Group type: COMPARATOR
Intervention: Nitrogen-Free Diet (NFD)
Number of subjects: 51
Study 33992285 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragm Manual Therapy (DMT)
Number of subjects: 40
Study 33992285 — intervention group
Group type: COMPARATOR
Intervention: Sham Diaphragm Technique (SDT)
Number of subjects: 40
Study 32750305 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (4×5 minutes)
Number of subjects: 12
Study 32750305 — intervention group
Group type: COMPARATOR
Intervention: Hand-grip exercise (4×5 minutes)
Number of subjects: 12
Study 33847743 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 pandemic
Number of subjects: 0
Study 32180481 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (CRT) with modulated electro-hyperthermia (mEHT)
Number of subjects: 206
Study 32180481 — intervention group
Group type: COMPARATOR
Intervention: Chemoradiotherapy (CRT) alone
Number of subjects: 206
Study 32180481 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (CRT) with mEHT
Number of subjects: 206
Study 35932196 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer Group Connection (PGC-HS)
Number of subjects: 1523
Study 35932196 — intervention group
Group type: COMPARATOR
Intervention: Classes-as-usual (Control)
Number of subjects: 1523
Study 32056539 — intervention group
Group type: EXPERIMENTAL
Intervention: Saffron extract (affron; 14 mg twice daily)
Number of subjects: 63
Study 32056539 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 35166788 — intervention group
Group type: EXPERIMENTAL
Intervention: Text-based model for home blood pressure monitoring
Number of subjects: 0
Study 35166788 — intervention group
Group type: COMPARATOR
Intervention: Online patient portal
Number of subjects: 0
Study 32221555 — intervention group
Group type: EXPERIMENTAL
Intervention: IPTp with SP
Number of subjects: 125
Study 32221555 — intervention group
Group type: COMPARATOR
Intervention: ISTp
Number of subjects: 125
Study 32221555 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent SP receipt (> 4 weeks before delivery)
Number of subjects: 125
Study 34296623 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive care values scale (10-point scale, 1 = 'do everything', 10 = 'live with whatever time I have left')
Number of subjects: 232
Study 34296623 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in treatment preferences (LVAD, unsure, no LVAD)
Number of subjects: 232
Study 34296623 — intervention group
Group type: EXPERIMENTAL
Intervention: Values score changes over time
Number of subjects: 232
Study 34296623 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of values score changes
Number of subjects: 232
Study 34296623 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of treatment preference change
Number of subjects: 232
Study 33461522 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated knowledge translation (IKT) strategy
Number of subjects: 0
Study 33461522 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to information and stakeholder/media engagement
Number of subjects: 0
Study 33461522 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge translation products
Number of subjects: 0
Study 33461522 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained engagement with diverse stakeholders
Number of subjects: 0
Study 34098192 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga therapy (YT)
Number of subjects: 51
Study 34098192 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (WL)
Number of subjects: 51
Study 34098192 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (YT and WL)
Number of subjects: 51
Study 34785718 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictable condition with leftward velocity fixed at one of seven velocities (4, 8, 12, 16, 20, 24, or 28 deg/s)
Number of subjects: 0
Study 34785718 — intervention group
Group type: EXPERIMENTAL
Intervention: Unpredictable condition with leftward velocity randomized
Number of subjects: 0
Study 34785718 — intervention group
Group type: EXPERIMENTAL
Intervention: Both predictable and unpredictable conditions
Number of subjects: 0
Study 34785718 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear mixed‐effects (LME) model
Number of subjects: 0
Study 32006590 — intervention group
Group type: EXPERIMENTAL
Intervention: A combination of atomoxetine and oxybutynin (ato-oxy)
Number of subjects: 23
Study 32006590 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine alone
Number of subjects: 23
Study 32006590 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin alone
Number of subjects: 23
Study 32006590 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 35264368 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile patient lift protocol
Number of subjects: 0
Study 35264368 — intervention group
Group type: COMPARATOR
Intervention: No mobile lift protocol (Control)
Number of subjects: 0
Study 34110954 — intervention group
Group type: EXPERIMENTAL
Intervention: Second- or third-generation ALK inhibitors after crizotinib therapy
Number of subjects: 0
Study 34110954 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid biopsy
Number of subjects: 0
Study 32641291 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenting and agribusiness combined
Number of subjects: 248
Study 32641291 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenting only
Number of subjects: 248
Study 32641291 — intervention group
Group type: EXPERIMENTAL
Intervention: Agribusiness only
Number of subjects: 248
Study 32641291 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 248
Study 35451976 — intervention group
Group type: EXPERIMENTAL
Intervention: YFS+APP (youth-friendly PrEP services plus use of a PrEP adherence support app)
Number of subjects: 200
Study 35451976 — intervention group
Group type: COMPARATOR
Intervention: YFS (youth-friendly PrEP services)
Number of subjects: 200
Study 34023342 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical mupirocin (5-day course)
Number of subjects: 205
Study 34023342 — intervention group
Group type: COMPARATOR
Intervention: Petroleum jelly (control group)
Number of subjects: 205
Study 32989836 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematized phonics
Number of subjects: 49
Study 32989836 — intervention group
Group type: COMPARATOR
Intervention: Classroom instruction
Number of subjects: 49
Study 36037014 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise combined with TCM herbal tea (six substances) taken once daily besides exercise.
Number of subjects: 75
Study 36037014 — intervention group
Group type: COMPARATOR
Intervention: Aerobic and resistance exercise three times per week.
Number of subjects: 75
Study 33272034 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D‐OFDI‐guided PCI
Number of subjects: 110
Study 33272034 — intervention group
Group type: COMPARATOR
Intervention: Angiography‐guided PCI
Number of subjects: 110
Study 34670012 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) 900 mg, twice daily
Number of subjects: 20
Study 34670012 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 33635382 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil infusion
Number of subjects: 60
Study 33635382 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study 32795903 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV: n = 6: IPAP = 20 ± 2, EPAP: 3 cmH2O)
Number of subjects: 9
Study 32795903 — intervention group
Group type: COMPARATOR
Intervention: Sham (n = 3: IPAP = 5, EPAP: 3 cmH2O)
Number of subjects: 9
Study 36271410 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxemia (PaO2 < 60 mmHg)
Number of subjects: 1418
Study 36271410 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxemia (PaO2 > 300 mmHg)
Number of subjects: 1418
Study 36271410 — intervention group
Group type: EXPERIMENTAL
Intervention: PaO2-AUC for hyperoxemia
Number of subjects: 1418
Study 34161846 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatic cell genome editing (SCGE)
Number of subjects: 46
Study 34161846 — intervention group
Group type: EXPERIMENTAL
Intervention: NIH funding criteria for SCGE research
Number of subjects: 46
Study 33596832 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (AE)
Number of subjects: 20
Study 33596832 — intervention group
Group type: COMPARATOR
Intervention: Isometric exercise (IE)
Number of subjects: 20
Study 35834254 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II Receptor Blockers (ARB)
Number of subjects: 9361
Study 35834254 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin-Converting Enzyme Inhibitors (ACEI)
Number of subjects: 9361
Study 35834254 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II Receptor Blockers (ARB) in standard systolic blood pressure treatment arm
Number of subjects: 9361
Study 35834254 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin-Converting Enzyme Inhibitors (ACEI) in standard systolic blood pressure treatment arm
Number of subjects: 9361
Study 35834254 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II Receptor Blockers (ARB) in intensive systolic blood pressure treatment arm
Number of subjects: 9361
Study 35834254 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin-Converting Enzyme Inhibitors (ACEI) in intensive systolic blood pressure treatment arm
Number of subjects: 9361
Study 34496173 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile Stroke Units (MSU)
Number of subjects: 1515
Study 34496173 — intervention group
Group type: COMPARATOR
Intervention: Emergency Medical Services (EMS)
Number of subjects: 1515
Study 32748572 — intervention group
Group type: EXPERIMENTAL
Intervention: Retraining and Control Therapy (ReACT); 8 sessions
Number of subjects: 32